Apricus Biosciences competitors
Apricus Biosciences Competitors include Biogen, MyoKardia, Athersys and Reata Pharmaceuticals.
Add company...
You can compare up to 12 companies. Please remove a company to add a new one
| Save ComparisonClear all |  Apricus Biosciences Apricus Biosciences is a pharmaceutical company that develops and markets innovative treatments for sexual health. |  Biogen Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases. |  MyoKardia MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. |  Athersys Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications. |  Reata Pharmaceuticals Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. |
Founding Date | Founding Date 1987 | Founding Date 1978 | Founding Date 2012 | Founding Date 1995 | Founding Date 2002 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations San Diego, US HQ | Locations Cambridge, US HQ | Locations South San Francisco, US HQ | Locations Cleveland, US HQ Canton, US | Locations Irving, US HQ |
Employees | Employees 15 | Employees 7,300 | Employees 1024% increase | Employees 66 | Employees 9324% increase |
Valuation ($) | Valuation ($) 6.2 m | Valuation ($) 65.5 b | Valuation ($) 1.7 b | Valuation ($) 216.9 m | Valuation ($) N/A |
Twitter followers | Twitter followers 750 | Twitter followers 19.4 k | Twitter followers 387 | Twitter followers 953 | Twitter followers 418 |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $11.4b (FY, 2016) | Revenue (est.) $22.5m (FY, 2017) | Revenue (est.) $3.7m (FY, 2017) | Revenue (est.) $48.1m (FY, 2017) |
Net income | Net income $321k (FY, 2017) | Net income $3.7b (FY, 2016) | Net income ($46m) (FY, 2017) | Net income N/A | Net income ($47.7m) (FY, 2017) |
Operating ⚠ | |||||
Patents (US) | Patents (US) N/A | Patents (US) N/A | Patents (US) 4 (FY, 2017) | Patents (US) 21 (FY, 2016) | Patents (US) N/A |
Patents Issued | Patents Issued N/A | Patents Issued N/A | Patents Issued N/A | Patents Issued 200 (FY, 2016) | Patents Issued 240 (FY, 2016) |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 4 (FY, 2016) | Phase I Trials Products 2 (FY, 2017) | Phase I Trials Products N/A | Phase I Trials Products 2 (FY, 2016) |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products 10 (FY, 2016) | Phase II Trials Products 1 (FY, 2017) | Phase II Trials Products N/A | Phase II Trials Products 4 (FY, 2016) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 2 (FY, 2016) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 1 (FY, 2016) |
Funding | |||||
Total funding raised | Total funding raised $ 12.3m | Total funding raised N/A | Total funding raised $ 98m | Total funding raised $ 9m | Total funding raised $ 300m |
For sources of this data, please see the company profileDownload Excel
View company profiles
Biogen
HQ
Cambridge, US
Employees
7,300
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.
View companyMyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
View companyAthersys
HQ
Cleveland, US
Employees
66
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
View companyReata Pharmaceuticals
HQ
Irving, US
Employees
93↑ 24% increase
Reata Pharmaceuticals is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases.
View company